Clinical significance of both tumor and stromal expression of components of the IL-1 and TNF-α signaling pathways in prostate cancer

Rodríguez-Berriguete, Gonzalo; Sánchez-Espiridión, Beatriz; Cansino, José R.; Olmedilla, Gabriel; Martínez-Onsurbe, Pilar; Sánchez‐Chapado, Manuel; Paniagua, Ricardo; Fraile, Benito; Royuela, Mar

doi:10.1016/j.cyto.2013.09.003

Cited by 57 publications

(44 citation statements)

References 60 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This is corroborated by other studies demonstrating an increase in TNF-α in organisms with established tumors and suggests that it may be a marker of the extent of disease. [25][26][27] It is also known that chemotherapy can induce TNF-α production, which can signal proapoptotic or mitogenic pathways. [4,5] However, in the presence of chemotherapy, it appears that CR decreases circulating levels of TNF-α which may be a sign of decreased systemic disease progression as seen in a pilot clinical trial in BCa patients.…”

Section: Discussionmentioning

confidence: 99%

Caloric restriction counteracts chemotherapy-induced inflammation and increases response to therapy in a triple negative breast cancer model

et al. 2018

View full text Add to dashboard Cite

Triple negative breast cancer (TNBC) is a heterogeneous disease that has no available targeted therapies. Previously, we have shown that caloric restriction (CR) can augment the effects of radiation therapy in a TNBC mouse model. To build upon this, we now present data regarding the combination of chemotherapy and CR in the same 4T1 model. Chemotherapy can induce inflammation that breeds resistance to therapy. We propose CR as a mechanism to decrease chemotherapy-induced inflammation and increase efficacy of therapy. 12-week old Balb/c mice were orthotopically injected with a syngeneic triple negative breast cancer cell line (4T1) and were treated in one of six cohorts: ad lib fed (AL), 30% reduction in calorie intake (CR), cisplatin or docetaxol alone or a combination CR+cisplatin/docetaxol. Mice in the cohorts receiving chemotherapy+CR had longer overall survival (12 ± 2 days) as compared to the AL group. These mice also demonstrated less lung metastases at the final time point of in vivo imaging. In addition, downregulation of the IGF-1R and IRS signaling pathways were noted most significantly in those mice receiving combination therapy. Lastly, serum from these mice demonstrated an increase in inflammatory cytokines TNF-α and IL-1β in response to chemotherapy alone. This increase was dampened by the addition of CR. Taken together, these data suggest that while chemotherapy is effective in TNBC, it can cause inflammation, which can be a driver of resistance to therapy. This chemotherapy-induced inflammation can be reversed with the use of CR as a nontoxic adjunct to treatment.

show abstract

Section: Discussionmentioning

confidence: 99%

Caloric restriction counteracts chemotherapy-induced inflammation and increases response to therapy in a triple negative breast cancer model

et al. 2018

View full text Add to dashboard Cite

show abstract

“…The pro‐inflammatory cytokine TNFα is over‐expressed in PCa specimens (Rodriguez‐Berriguete et al., 2013), and it may contribute to prostate carcinogenesis and neoplastic progression (De Marzo et al., 2007). Notably, high TNFα expression has been associated with poor PCa prognosis (Rodriguez‐Berriguete et al., 2013). GHRH was first discovered as a hypothalamic neuropeptide (Bowers, 2012).…”

Section: Discussionmentioning

confidence: 99%

Integrated analysis of the prostate cancer small‐nucleolar transcriptome reveals SNORA55 as a driver of prostate cancer progression

et al. 2015

View full text Add to dashboard Cite

Metastasis is the primary cause of death in prostate cancer (PCa) patients. Small nucleolar RNAs (snoRNAs) have long been considered “housekeeping” genes with no relevance for cancer biology. Emerging evidence has challenged this assumption, suggesting that snoRNA expression is frequently modulated during cancer progression. Despite this, no study has systematically addressed the prognostic and functional significance of snoRNAs in PCa.We performed RNA Sequencing on paired metastatic/non‐metastatic PCa xenografts derived from clinical specimens. The clinical significance of differentially expressed snoRNAs was further investigated in two independent primary PCa cohorts (131 and 43 patients, respectively). The snoRNA demonstrating the strongest association with clinical outcome was quantified in PCa patient‐derived serum samples and its functional relevance was investigated in PCa cells via gene expression profiling, pathway analysis and gene silencing.Our comparison revealed 21 differentially expressed snoRNAs in the metastatic vs. non‐metastatic xenografts. Of those, 12 were represented in clinical databases and were further analyzed. SNORA55 emerged as a predictor of shorter relapse‐free survival (results confirmed in two independent databases). SNORA55 was reproducibly detectable in serum samples from PCa patients. SNORA55 silencing in PCa cell lines significantly inhibited cell proliferation and migration. Pathway analysis revealed that SNORA55 expression is significantly associated with growth factor signaling and pro‐inflammatory cytokine expression in PCa.Our results demonstrate that SNORA55 up‐regulation predicts PCa progression and that silencing this non‐coding gene affects PCa cell proliferation and metastatic potential, thus positioning it as both a novel biomarker and therapeutic target.

show abstract

“…About 20% of human cancers are related to dysregulated inflammation caused by infections, exposure to irritants or autoimmune diseases . A number of molecules in the inflammatory pathways have been shown to have predicative value in cancers.…”

Section: Discussionmentioning

confidence: 99%

“…For example, TNF‐α, the overexpression of which coincides with cancer, has been used for determining cancer risk and is a target of cancer therapy . The prognostic value of IL‐1β in prostate, colon, lung cancers and GC has also been reported. Notwithstanding the crucial role of IL‐1α in cancer, results from published studies on the role of IL‐1α in cancer are confusing rather than conclusive due to the fact that polymorphisms of IL‐ 1α may lead to opposing effects on cancer progression.…”

Section: Discussionmentioning

confidence: 99%

Hypoxia/IL‐1α axis promotes gastric cancer progression and drug resistance

Yao

Wang

2017

J of Digest Diseases

View full text Add to dashboard Cite

show abstract

Clinical significance of both tumor and stromal expression of components of the IL-1 and TNF-α signaling pathways in prostate cancer

Cited by 57 publications

References 60 publications

Caloric restriction counteracts chemotherapy-induced inflammation and increases response to therapy in a triple negative breast cancer model

Caloric restriction counteracts chemotherapy-induced inflammation and increases response to therapy in a triple negative breast cancer model

Integrated analysis of the prostate cancer small‐nucleolar transcriptome reveals SNORA55 as a driver of prostate cancer progression

Hypoxia/IL‐1α axis promotes gastric cancer progression and drug resistance

Contact Info

Product

Resources

About